AP616A - Treatment of post-herpetic neuralgia with antiviral guanine derivatives. - Google Patents
Treatment of post-herpetic neuralgia with antiviral guanine derivatives. Download PDFInfo
- Publication number
- AP616A AP616A APAP/P/1994/000684A AP9400684A AP616A AP 616 A AP616 A AP 616A AP 9400684 A AP9400684 A AP 9400684A AP 616 A AP616 A AP 616A
- Authority
- AP
- ARIPO
- Prior art keywords
- famciclovir
- treatment
- patients
- placebo
- pain
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 45
- 206010036376 Postherpetic Neuralgia Diseases 0.000 title description 64
- 230000000840 anti-viral effect Effects 0.000 title description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 20
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 54
- 229960004396 famciclovir Drugs 0.000 claims description 52
- 150000001875 compounds Chemical class 0.000 claims description 30
- 208000010201 Exanthema Diseases 0.000 claims description 23
- 201000005884 exanthem Diseases 0.000 claims description 23
- 206010037844 rash Diseases 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- -1 phosphate ester Chemical class 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 description 49
- 229940068196 placebo Drugs 0.000 description 45
- 239000000902 placebo Substances 0.000 description 45
- 208000002193 Pain Diseases 0.000 description 42
- 230000036407 pain Effects 0.000 description 35
- 229940097919 famciclovir 500 mg Drugs 0.000 description 22
- 230000001154 acute effect Effects 0.000 description 21
- 229940104320 famciclovir 750 mg Drugs 0.000 description 20
- 230000003902 lesion Effects 0.000 description 19
- 230000035876 healing Effects 0.000 description 18
- 229960004150 aciclovir Drugs 0.000 description 13
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 230000002354 daily effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 206010039509 Scab Diseases 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 9
- 229960001179 penciclovir Drugs 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 7
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 5
- KGSIOVLUJYQLKR-UHFFFAOYSA-N [[4-(2-amino-6-oxo-3h-purin-9-yl)-2-(hydroxymethyl)butoxy]-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=N2 KGSIOVLUJYQLKR-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 230000007485 viral shedding Effects 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000004404 Intractable Pain Diseases 0.000 description 3
- AYWLSIKEOSXJLA-UHFFFAOYSA-N [2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]ethoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=N2 AYWLSIKEOSXJLA-UHFFFAOYSA-N 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 208000030090 Acute Disease Diseases 0.000 description 2
- 206010060933 Adverse event Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000003136 immunomodifying effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000002420 orchard Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- BRPTUOYNOCSFRJ-FYZOBXCZSA-N sodium (2S)-4-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)butan-1-olate Chemical class [Na+].Nc1nc(=O)c2ncn(CC[C@H](CO)C[O-])c2[nH]1 BRPTUOYNOCSFRJ-FYZOBXCZSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939320485A GB9320485D0 (en) | 1993-10-05 | 1993-10-05 | Pharmaceuticals |
| GB939321255A GB9321255D0 (en) | 1993-10-14 | 1993-10-14 | Pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9400684A0 AP9400684A0 (en) | 1994-10-31 |
| AP616A true AP616A (en) | 1997-09-15 |
Family
ID=26303637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1994/000684A AP616A (en) | 1993-10-05 | 1994-10-05 | Treatment of post-herpetic neuralgia with antiviral guanine derivatives. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5866581A (da) |
| EP (1) | EP0804199B1 (da) |
| JP (1) | JP3768527B2 (da) |
| CN (1) | CN1082816C (da) |
| AP (1) | AP616A (da) |
| AT (1) | ATE216885T1 (da) |
| AU (1) | AU7788494A (da) |
| CA (1) | CA2173505C (da) |
| CY (1) | CY2375B1 (da) |
| DE (1) | DE69430545T2 (da) |
| DK (1) | DK0804199T3 (da) |
| ES (1) | ES2176258T3 (da) |
| HU (1) | HU226472B1 (da) |
| IL (1) | IL111138A (da) |
| PT (1) | PT804199E (da) |
| WO (1) | WO1995009632A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9600847D0 (en) | 1996-01-16 | 1996-03-20 | Smithkline Beecham Plc | Pharmaceuticals |
| ATE279188T1 (de) * | 1998-07-09 | 2004-10-15 | Warner Lambert Co | Pharmazeutische zusammensetzungen enthaltend gaba-analogen und ein antivirales mittel zur behandlung von herpes zoster |
| US6419934B1 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | TNF modulators for treating neurological disorders associated with viral infection |
| WO2007037790A2 (en) * | 2005-06-08 | 2007-04-05 | Elan Corporation, Plc | Modified release famciclovir compositions |
| EP2846788A1 (en) * | 2012-05-11 | 2015-03-18 | Akron Molecules AG | Use of compounds for the treatment of pain |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0141927A2 (en) * | 1983-08-18 | 1985-05-22 | Beecham Group Plc | Antiviral guanine derivatives |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3582399D1 (de) * | 1984-09-20 | 1991-05-08 | Beecham Group Plc | Purin-derivate und ihre pharmazeutische verwendung. |
-
1994
- 1994-10-03 IL IL111138A patent/IL111138A/xx not_active IP Right Cessation
- 1994-10-04 AT AT94928459T patent/ATE216885T1/de active
- 1994-10-04 CA CA002173505A patent/CA2173505C/en not_active Expired - Lifetime
- 1994-10-04 ES ES94928459T patent/ES2176258T3/es not_active Expired - Lifetime
- 1994-10-04 CN CN94194138A patent/CN1082816C/zh not_active Expired - Lifetime
- 1994-10-04 HU HU9600882A patent/HU226472B1/hu unknown
- 1994-10-04 JP JP51069095A patent/JP3768527B2/ja not_active Expired - Lifetime
- 1994-10-04 WO PCT/GB1994/002156 patent/WO1995009632A1/en not_active Ceased
- 1994-10-04 PT PT94928459T patent/PT804199E/pt unknown
- 1994-10-04 EP EP94928459A patent/EP0804199B1/en not_active Expired - Lifetime
- 1994-10-04 US US08/624,466 patent/US5866581A/en not_active Expired - Lifetime
- 1994-10-04 DK DK94928459T patent/DK0804199T3/da active
- 1994-10-04 DE DE69430545T patent/DE69430545T2/de not_active Expired - Lifetime
- 1994-10-04 AU AU77884/94A patent/AU7788494A/en not_active Abandoned
- 1994-10-05 AP APAP/P/1994/000684A patent/AP616A/en active
-
2003
- 2003-08-25 CY CY0300059A patent/CY2375B1/xx unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0141927A2 (en) * | 1983-08-18 | 1985-05-22 | Beecham Group Plc | Antiviral guanine derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| AP9400684A0 (en) | 1994-10-31 |
| CN1135180A (zh) | 1996-11-06 |
| CA2173505A1 (en) | 1995-04-13 |
| HU9600882D0 (en) | 1996-05-28 |
| EP0804199A1 (en) | 1997-11-05 |
| ATE216885T1 (de) | 2002-05-15 |
| US5866581A (en) | 1999-02-02 |
| CY2375B1 (en) | 2004-06-04 |
| WO1995009632A1 (en) | 1995-04-13 |
| DE69430545T2 (de) | 2002-11-07 |
| HUT74076A (en) | 1996-10-28 |
| HK1004115A1 (en) | 1998-11-20 |
| AU7788494A (en) | 1995-05-01 |
| IL111138A (en) | 1997-04-15 |
| DK0804199T3 (da) | 2002-08-19 |
| DE69430545D1 (de) | 2002-06-06 |
| ES2176258T3 (es) | 2002-12-01 |
| EP0804199B1 (en) | 2002-05-02 |
| JP3768527B2 (ja) | 2006-04-19 |
| CN1082816C (zh) | 2002-04-17 |
| HU226472B1 (en) | 2008-12-29 |
| PT804199E (pt) | 2002-09-30 |
| JPH10513434A (ja) | 1998-12-22 |
| IL111138A0 (en) | 1994-12-29 |
| CA2173505C (en) | 2005-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spruance et al. | Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol | |
| Tyring et al. | Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial | |
| EP0804199B1 (en) | Use of penciclovir for the treatment of post herpetic neuralgia | |
| Goodman et al. | Prospective double-blind evaluation of topical adenine arabinoside in male herpes progenitalis | |
| US6124304A (en) | Penciclovir for the treatment of zoster associated pain | |
| HK1004115B (en) | Use of penciclovir for the treatment of post herpetic neuralgia | |
| Whitley et al. | Herpes zoster: focus on treatment in older adults | |
| AU696833B2 (en) | Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 infection | |
| JP6018473B2 (ja) | １日１回処置を使用する再発性口唇ヘルペスの処置のためのファムシクロビル | |
| de Bony et al. | Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid | |
| AU7860394A (en) | Use of peniclorin for the treatment of posttherapeutic neuralgia | |
| KR20250008441A (ko) | 질환의 치료 방법 | |
| KR20180077138A (ko) | Ｎ-메타노카르바티미딘(n-mct)을 사용한 대상포진의 치료 방법 | |
| EP0735878A1 (en) | Pharmaceuticals | |
| EP2394651A1 (en) | Penciclovir or Famciclovir for the Treatment of Recurrent Genital Herpes With a One-Day Application | |
| US20150011568A1 (en) | Famciclovir for the Treatment of Recurrent Herpes Labialis Using a One-Day Treatment |